Luo, Mao
Xu, Chunrong
Luo, Yulin
Wang, Gang
Wu, Jianbo
Wan, Qin http://orcid.org/0000-0001-7310-7704
Funding for this research was provided by:
National Natural Science Foundation of China (81800434, 81570263)
Department of Science and Technology of Sichuan Province (2019YJ0487)
Ministry of Science and Technology of the People's Republic of China (2016YFC0901200, 2016YFC0901205)
Luzhou Municipal Science and Technology Bureau (2017LZXNYD-T05, 2016LZXNYD-J24)
Article History
Received: 5 August 2019
Accepted: 23 September 2019
First Online: 3 October 2019
Compliance with ethical standards
:
: All the authors including Mao Luo, Chunrong Xu, Yulin Luo, Gang Wang, Jianbo Wu, and Qin Wan declare that they have no conflict of interest.
: All human subjects used in the study ‘‘Circulating miR-103 Family as Potential Biomarkers for Type 2 Diabetes through targeting CAV-1 and SFRP4’’ have been reviewed by the Research Ethics Committee of the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, P. R. China and have been performed in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All samples were collected with informed consent of all subjects. There is no security and privacy violation to the patient’s health in our study.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the 1975 Helsinki declaration, as revised in 2008 (5).
: Informed consent was obtained from all individual participants included in the study.